These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 28450567

  • 1. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer: 18F-FDG PET/CT Study.
    Morbelli S, Alama A, Ferrarazzo G, Coco S, Genova C, Rijavec E, Bongioanni F, Biello F, Dal Bello MG, Barletta G, Massollo M, Vanni I, Piva R, Nieri A, Bauckneht M, Sambuceti G, Grossi F.
    J Nucl Med; 2017 Nov; 58(11):1764-1769. PubMed ID: 28450567
    [Abstract] [Full Text] [Related]

  • 2. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F, Wu X, Zhu J, Huang Y, Song X, Jiang L.
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [Abstract] [Full Text] [Related]

  • 3. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A, Mohan A, Bhalla AS, Sharma MC, Vishnubhatla S, Das CJ, Pandey AK, Sekhar Bal C, Patel CD, Sharma P, Agarwal KK, Kumar R.
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [Abstract] [Full Text] [Related]

  • 4. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.
    Sun M, Lu D, Li X, Wang J, Zhang L, Yang P, Yang Y, Shen J.
    Cancer Med; 2024 Sep; 13(18):e70216. PubMed ID: 39302034
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR, Chung SK, Park HL, Choi WH, Kim YK, Lee KY, Wang YP.
    Biomed Mater Eng; 2014 Sep; 24(6):3091-103. PubMed ID: 25227018
    [Abstract] [Full Text] [Related]

  • 6. Combining 18F-FDG PET/CT-Based Metabolically Active Tumor Volume and Circulating Cell-Free DNA Significantly Improves Outcome Prediction in Chemorefractory Metastatic Colorectal Cancer.
    Woff E, Kehagias P, Vandeputte C, Ameye L, Guiot T, Paesmans M, Hendlisz A, Flamen P.
    J Nucl Med; 2019 Oct; 60(10):1366-1372. PubMed ID: 30850494
    [Abstract] [Full Text] [Related]

  • 7. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
    Pellegrino S, Fonti R, Mazziotti E, Piccin L, Mozzillo E, Damiano V, Matano E, De Placido S, Del Vecchio S.
    Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
    [Abstract] [Full Text] [Related]

  • 8. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer.
    Sahiner I, Atasever T, Akdemir UO, Ozturk C, Memis L.
    Rev Esp Med Nucl Imagen Mol; 2013 Dec; 32(6):357-63. PubMed ID: 23747221
    [Abstract] [Full Text] [Related]

  • 9. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Castello A, Toschi L, Rossi S, Finocchiaro G, Grizzi F, Mazziotti E, Qehajaj D, Rahal D, Lopci E.
    Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
    [Abstract] [Full Text] [Related]

  • 10. Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.
    Tixier F, Vriens D, Cheze-Le Rest C, Hatt M, Disselhorst JA, Oyen WJ, de Geus-Oei LF, Visser EP, Visvikis D.
    J Nucl Med; 2016 Jul; 57(7):1033-9. PubMed ID: 26966161
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 12. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A, Duan F, Snyder BS, Wei B, Houshmand S, Khiewvan B, Opanowski A, Simone CB, Siegel BA, Machtay M, Alavi A.
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [Abstract] [Full Text] [Related]

  • 13. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
    Kramer GM, Frings V, Hoetjes N, Hoekstra OS, Smit EF, de Langen AJ, Boellaard R.
    J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
    [Abstract] [Full Text] [Related]

  • 14. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.
    Burger IA, Casanova R, Steiger S, Husmann L, Stolzmann P, Huellner MW, Curioni A, Hillinger S, Schmidtlein CR, Soltermann A.
    J Nucl Med; 2016 Jun; 57(6):849-54. PubMed ID: 26823566
    [Abstract] [Full Text] [Related]

  • 15. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer.
    Yıldırım F, Yurdakul AS, Özkaya S, Akdemir ÜÖ, Öztürk C.
    Clin Respir J; 2017 Sep; 11(5):602-611. PubMed ID: 26434685
    [Abstract] [Full Text] [Related]

  • 16. Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
    Soussan M, Cyrta J, Pouliquen C, Chouahnia K, Orlhac F, Martinod E, Eder V, Morère JF, Buvat I.
    Radiology; 2014 Sep; 272(3):875-84. PubMed ID: 24761836
    [Abstract] [Full Text] [Related]

  • 17. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
    Ding CY, Guo Z, Li YY, Li TR.
    Zhonghua Zhong Liu Za Zhi; 2017 Nov 23; 39(11):828-834. PubMed ID: 29151289
    [Abstract] [Full Text] [Related]

  • 18. Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.
    Winther-Larsen A, Demuth C, Fledelius J, Madsen AT, Hjorthaug K, Meldgaard P, Sorensen BS.
    Br J Cancer; 2017 Aug 22; 117(5):704-709. PubMed ID: 28683468
    [Abstract] [Full Text] [Related]

  • 19. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zaizen Y, Azuma K, Kurata S, Sadashima E, Hattori S, Sasada T, Imamura Y, Kaida H, Kawahara A, Kinoshita T, Ishibashi M, Hoshino T.
    Eur J Radiol; 2012 Dec 22; 81(12):4179-84. PubMed ID: 22884163
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Vu CC, Matthews R, Kim B, Franceschi D, Bilfinger TV, Moore WH.
    Nucl Med Commun; 2013 Oct 22; 34(10):959-63. PubMed ID: 23921784
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.